Evidence map›Paper›PMID 33212152›Full record

ArticleThe Journal of investigative dermatology2021

Epigenetic Alterations in Keratinocyte Carcinoma.

Qiuming Yao, Charles B Epstein, Samridhi Banskota, Robbyn Issner, Yuhree Kim, Bradley E Bernstein, Luca Pinello, Maryam M Asgari

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. From Enhancers to Keratinocyte Cancers.The Journal of investigative dermatology · 2021
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qiuming YaoDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Charles B EpsteinBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Samridhi BanskotaBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Robbyn IssnerBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Yuhree KimDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Bradley E BernsteinDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Luca PinelloDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Electronic address: lpinello@mgh.harvard.edu.
Maryam M AsgariDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Broad Institute · USHarvard University · USMassachusetts General Hospital · US

Funding

A Catalog of Cell Types and Genomic Elements in Tissues, Organoids and DiseaseUM1HG009390 · NHGRI · BROAD INSTITUTE, INC. · PI BERNSTEIN, BRADLEY EVAN · 2017 to 2021
$11.0M
Multiscale exploration of the functional non-coding genomeR35HG010717 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI PINELLO, LUCA · 2019 to 2023
$2.6M
Patient-oriented research and mentoring program in dermatologic diseasesK24AR069760 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA · 2017 to 2025
$1.9M
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progressionR01CA231264 · NCI · UNIVERSITY OF COLORADO DENVER · PI ASGARI, MARYAM MANDANA · 2019 to 2023
$1.5M
Discovering disease-causal variants by linking genetic and epigenetic variationR00HG008399 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI PINELLO, LUCA · 2017 to 2019
$747k
NCI NIH HHS R01 CA231264NHGRI NIH HHS R00 HG008399NHGRI NIH HHS R35 HG010717NHGRI NIH HHS UM1 HG009390NIAMS NIH HHS K24 AR069760
6 · The paper itself

Abstract

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are both derived from epidermal keratinocytes but are phenotypically diverse. To improve the understanding of keratinocyte carcinogenesis, it is critical to understand epigenetic alterations, especially those that govern gene expression. We examined changes to the enhancer-associated histone acetylation mark H3K27ac by mapping matched tumor-normal pairs from 11 patients (five with BCC and six with SCC) undergoing Mohs surgery. Our analysis uncovered cancer-specific enhancers on the basis of differential H3K27ac peaks between matched tumor-normal pairs. We also uncovered biological pathways potentially altered in keratinocyte carcinoma, including enriched epidermal development and Wnt signaling pathways enriched in BCCs and enriched immune response and cell activation pathways in SCCs. We also observed enrichment of transcription factors that implicated SMAD and JDP2 in BCC pathogenesis and FOXP1 in SCC pathogenesis. On the basis of these findings, we prioritized three loci with putative regulation events (FGFR2 enhancer in BCC, intragenic regulation of FOXP1 in SCC, and WNT5A promoter in both subtypes) and validated our findings with published gene expression data. Our findings highlight unique and shared epigenetic alterations in histone modifications and potential regulators for BCCs and SCCs that likely impact the divergent oncogenic pathways, paving the way for targeted drug discoveries.

Indexed as

Epigenesis, GeneticAgedAged, 80 and overBasal Cell CarcinomaCarcinoma, Squamous CellEnhancer Elements, GeneticFemaleHumansMaleMiddle AgedReceptor, Fibroblast Growth Factor, Type 2Skin NeoplasmsTranscription, GeneticTranscriptomeWnt-5a ProteinFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2Wnt-5a ProteinWNT5A protein, human

Identifiers

PMID33212152
PMCPMC8068579
OpenAlexW3104120844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.